The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Aprepitant Has Mixed Effects on Nausea and Reduces Other Symptoms in Patients With Gastroparesis and Related Disorders
Open accessAbstract
Background & aims There are few effective treatments for nausea and other symptoms in patients with gastroparesis and related syndromes. We performed a randomized trial of the ability of the neurokinin-1 receptor antagonist aprepitant to reduce symptoms in patients with chronic nausea and vomiting caused by gastroparesis or gastroparesis-like syndrome. Methods We conducted a 4-week multicenter, double-masked trial of 126 patients with at least moderate symptoms of chronic nausea and vomiting of presumed gastric origin for a minimum of 6 months. Patients were randomly assigned to groups given oral aprepitant (125 mg/day, n = 63) or placebo (n = 63). The primary outcome from the intention-to-treat analysis was reduction in nausea, defined as a decrease of 25 mm or more, or absolute level below 25 mm, on a daily patient-reported 0-to-100 visual analog scale (VAS) of nausea severity. We calculated relative risks of nausea improvement using stratified Cochran-Mental-Haenszel analysis. Results Aprepitant did not reduce symptoms of nausea, based on the primary outcome measure (46% reduction in the VAS score in the aprepitant group vs 40% reduction in the placebo group; relative risk, 1.2; 95% CI, 0.8-1.7) (P = .43). However, patients in the aprepitant group had significant changes in secondary outcomes such as reduction in symptom severity (measured by the 0-5 Gastroparesis Clinical Symptom Index) for nausea (1.8 vs 1.0; P = .005), vomiting (1.6 vs 0.5; P = .001), and overall symptoms (1.3 vs 0.7; P = .001). Adverse events, predominantly mild or moderate in severity grade, were more common in aprepitant (22 of 63 patients, 35% vs 11 of 63, 17% in the placebo group) (P = .04). Conclusions In a randomized trial of patients with chronic nausea and vomiting caused by gastroparesis or gastroparesis-like syndrome, aprepitant did not reduce the severity of nausea when reduction in VAS score was used as the primary outcome. However, aprepitant had varying effects on secondary outcomes of symptom improvement. These findings support the need to identify appropriate patient outcomes for trials of therapies for gastroparesis, including potential additional trials for aprepitant. ClinicalTrials.gov no: NCT01149369.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In a 4‐week, multicenter, randomized double‐masked trial of 126 adults with gastroparesis (and related syndromes), although oral aprepitant (125 mg) failed to significantly reduce nausea when measured by visual analog criteria, it achieved the secondary outcomes of significant reduction in nausea and vomiting severity index as measured by the Gastroparesis Clinical Symptom Index.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Svedlund, J., Sjödin, I., & Dotevall, G. (1988) · Digestive Diseases and Sciences · doi:10.1007/bf01535722 · Cited by 1,319
Assessment of gastric emptying using a low fat meal: establishment of international control values
Tougas, G. H., Eaker, E. Y., Abell, T. L., Abrahamsson, H., Boivin, M., Chen, J. D. Z., Hocking, M. P., Quigley, E. M. M., Koch, K. L., Tokayer, A., et al. (2000) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.02076.x · Cited by 676
Self-citationWarr, D. G., Hesketh, P. J., Gralla, R. J., Muss, H. B., Herrstedt, J., Eisenberg, P. D., Raftopoulos, H., Grunberg, S. M., Gabriel, M., Rodgers, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.050 · Cited by 464
NK1 (substance P) receptor antagonists – why are they not analgesic in humans?
Hill, R. (2000) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01502-9 · Cited by 462
Rentz, A. M., Kahrilas, P., Stanghellini, V., Tack, J., Talley, N. J., De la loge, C., Trudeau, E., Dubois, D., & Revicki, D. A. (2004) · Quality of Life Research · doi:10.1007/s11136-004-9567-x · Cited by 406
Revicki, D. A., Rentz, A. M., Dubois, D., Kahrilas, P. J., Stanghellini, V., Talley, N. J., & Tack, J. F. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01612.x · Cited by 382
Parkman, H. P., Yates, K. P., Hasler, W. L., Nguyen, L. A. B., Pasricha, P. J., Snape, W. J., Farrugia, G., Koch, K. L., Abell, T. L., McCallum, R. W., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.10.015 · Cited by 348
Self-citationCharacteristics of Patients With Chronic Unexplained Nausea and Vomiting and Normal Gastric Emptying
Pasricha, P. J., Colvin, R., Yates, K. P., Hasler, W. L., Abell, T. L., Ünalp–Arida, A., Nguyen, L. A. B., Farrugia, G., Koch, K. L., Parkman, H. P., et al. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.03.003 · Cited by 247
Self-citationBrown, J., Liu, H., Maggio, J. E., Vigna, S. R., Mantyh, P. W., & Basbaum, A. I. (1995) · The Journal of Comparative Neurology · doi:10.1002/cne.903560302 · Cited by 240
Gan, T. J., Apfel, C. C., Kovac, A. L., Philip, B. K., Singla, N., Minkowitz, H. S., Habib, A. S., Knighton, J., Carides, A. D., Zhang, H., et al. (2007) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000263277.35140.a3 · Cited by 223
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–144 of 144
Camilleri, M. (2026) · JAMA · doi:10.1001/jama.2026.12181 · Cited by 2
Wenn der Magen „nicht mehr richtig schafft“
Bravo, F., Lenglinger, J., Borbély, Y., & Wiest, R. (2023) · Schweizer Gastroenterologie · doi:10.1007/s43472-023-00100-x · Cited by 2
Gong, J. Y., Sivaratnam, D. A., Armstrong, E., Hebbard, G., Brett, A. J., & Fourlanos, S. (2023) · Internal Medicine Journal · doi:10.1111/imj.16221 · Cited by 3
Gastroparesis and Cancer-Related Gastroparesis in Palliative Care Patients
Davis, M. P., Soni, K., & Strobel, S. D. (2024) · Springer eBooks · doi:10.1007/978-3-319-31738-0_114-2 · Cited by 2
Antiemetic therapy for gastroparesis
Wo, J. M., McCallum, R. W., & Gonzalez, Z. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818586-5.00025-9 · Cited by 2
Self-citationGastroparesis and the brain-gut axis
Vélez, C. D., & Kuo, B. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818586-5.00009-0 · Cited by 2
Heckroth, M. A., Tansel, A., Mathur, P., Stocker, A. M., Cutts, T. F., & Abell, T. L. (2022) · Foregut The Journal of the American Foregut Society · doi:10.1177/26345161221092650 · Cited by 2
Self-citationAtkins, M., López, I. G., & Kuo, B. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00182-1 · Cited by 2
Gastroparesis: diagnostic and therapeutic advances.
Castro, D. B., Bellido, P. D. P., & Rodríguez, B. G. (2021) · Revista Andaluza de Patología Digestiva · doi:10.37352/2021442.1 · Cited by 2
Gastroparesis: Time to Reconsider Our Terminology?
Keszthelyi, D. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.12.055 · Cited by 2
Jehangir, A., & Parkman, H. P. (2019) · Encyclopedia of Gastroenterology · doi:10.1016/b978-0-12-801238-3.66016-6 · Cited by 2
Self-citationDiagnostic Testing and Pharmacotherapy in Gastroparesis
Surjanhata, B. C., & Kuo, B. (2023) · Springer eBooks · doi:10.1007/978-3-031-19671-3_42 · Cited by 1
Kellar, T., Basnayake, C., Biesiekierski, J. R., Burgell, R., Fitzpatrick, J., Hebbard, G., Ho, V., Kim, H., Knowles, S. R., Rayner, C. K., et al. (2026) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70456 · Cited by 1
Stefi, E., Koch, K. L., Brown, A. L., & Shaltout, H. A. (2019) · Integrative Gastroenterology and Hepatology · doi:10.18314/igh.v2i1.1715 · Cited by 1
Self-citationEvaluating response in gastroparesis: Patient reported outcome measures and survey instruments
Revicki, D. A., & Parkman, H. P. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818586-5.00033-8 · Cited by 1
Self-citationGottesman-Katz, L., Borlack, R. E., & Khlevner, J. (2022) · Springer eBooks · doi:10.1007/978-3-031-15229-0_44 · Cited by 1
Off‐label use of aprepitant for scleroderma‐associated nausea and vomiting: A case report
Jubran, B., Bolduc, J., Eng, A., Stapleton, M. P., & Wilson, B. (2019) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12851 · Cited by 1
The pyloric revolution: Patient selection
Clarke, J. O., & McCallum, R. W. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818586-5.00034-x · Cited by 1
Self-citationThe Physiology and Pharmacology of Diabetic Gastropathy Management
Dolan, R. D., Rohani, T. S., Muttineni, D., & Mashimo, H. L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00045-1 · Cited by 1
Gastrointestinal Disorders in Long-Term Care
Goldberg, R. J., & Jhurani, M. (2021) · Springer eBooks · doi:10.1007/978-3-030-30192-7_95 · Cited by 1
Upper Gastrointestinal Manifestations of Diabetes
Camilleri, M. (2021) · Wiley eBooks · doi:10.1002/9781119603207.ch22 · Cited by 1
Gastrointestinal Manifestations of Diabetes
Camilleri, M., & Bharucha, A. E. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch55 · Cited by 1
Effect of Aprepitant in Patient with Gastroparesis and Related Disorders
Jung, K., & Park, M. I. (2018) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2018.72.6.325
Medical Management of Gastroparesis
Bielefeldt, K., McKenzie, P., & Fang, J. C. (2019) · Springer eBooks · doi:10.1007/978-3-030-28929-4_4
A vision of the future for gastroparesis
Camilleri, M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818586-5.00040-5
Parkman, H. P., & McCallum, R. W. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818586-5.00032-6
Self-citationKoch, K. L. (2019) · Encyclopedia of Gastroenterology · doi:10.1016/b978-0-12-801238-3.66010-5
Self-citationShahsavari, D., & Parkman, H. P. (2019) · Springer eBooks · doi:10.1007/978-3-030-25626-5_5
Self-citationOglat, A., & Quigley, E. M. M. (2018) · Clinical gastroenterology · doi:10.1007/978-3-319-75856-5_7
Shahsavari, D., & Parkman, H. P. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813037-7.00018-2
Self-citationPrevention of recurrent cyclic vomiting syndrome episodes
Levinthal, D. J., Hasler, W. L., & Venkatesan, T. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821597-5.00014-9
Self-citationSantucci, N. R., & Kaul, A. (2022) · Springer eBooks · doi:10.1007/978-3-031-15229-0_24
Zheng, T., & Camilleri, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-13911-6.00033-5
Highlights from the Diabetes UK Professional Conference 2023
Bishop, K. (2023) · Prescriber · doi:10.1002/psb.2096
Karrento, K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95082-4.00048-7
Substance P in nausea and vomiting
Andrews, P. L. R., Rudd, J. A., & Sanger, G. J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-22194-1.00032-x
Gastroparesis and Cancer-Related Gastroparesis in Palliative Care Patients
Davis, M. P., Soni, K., & Strobel, S. D. (2024) · Springer eBooks · doi:10.1007/978-3-031-48991-4_114
Moond, V., Singh, S., Hayat, U., Patel, P. B., Archit, G. A. R. G., Ali, H., & Adler, D. G. (2025) · Minerva Gastroenterology · doi:10.23736/s2724-5985.24.03804-x
Gastroparesis needs to be detected and treated
Plotnikova, E. Y., & SUKHIKH, A. S. (2025) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2025-184
Pasricha, P. J., & Ge, P. S. (2025) · iGIE · doi:10.1016/j.igie.2025.09.014
Self-citationLa gastroparésie au cours du diabète : diagnostic et traitement
Bonaz, B. L. (2025) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2025.09.004
Goyal, O., Chowdhary, R., Sehgal, T., Joshi, T., Bhambri, A., Rampurawala, I. M., Sohi, G. S., Das, A., Arora, K., Vuthaluru, A. R., et al. (2026) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v17.i2.118616
Barman, S., Chevallay, M., Gisbertz, S. S., Hemelrijck, M. V., Byrne, B. E., Wijnhoven, B. P. L., Markar, S. R., Elliott, J. A., Bornschein, J., Pritchard, D. M., et al. (2026) · Gut · doi:10.1136/gutjnl-2025-337109
Metadata
- Authors
- Pasricha, P. J., Yates, K. P., Sarosiek, I., McCallum, R. W., Abell, T. L., Koch, K. L., Nguyen, L. A. B., Snape, W. J., Hasler, W. L., Clarke, J. O., Dhalla, S., Stein, E. M., Lee, L. A., Miriel, L. A., Van Natta, M. L., Grover, M., Farrugia, G., Tonascia, J., Hamilton, F. A., Parkman, H. P., Snape, W. J., DeVole, N., Earle, K., Kirkeby, K., Lee, C., Lin, M., Ponting, K., Yee, G., Pasricha, P. J., Clarke, J. O., Stein, E., Dhalla, S., Kim, Y., Nguyen, L. A. B., Garay, G., Orlando, C., Parkman, H. P., Mauer, A., Orthey, P., Palit, A., McCallum, R. W., Sarosiek, I., Connery, S., Gomez, Y., Romero, R., Vega, N., Alvarado, B., Abell, T. L., Hatter, L., Howard, R., Nowotny, L., Hasler, W. L., Herman, W., Kraftson, A., Rothberg, A. E., Wootten, S., Koch, K. L., Baxter, L., Brown, A., Stuart, P., Culler, S., Farrugia, G., Grover, M., Bernard, C., Hamilton, F., Serrano, J., James, S., Torrance, R., Hall, S., Tonascia, J., Belt, P., Dodge, J., Donithan, M., Hallinan, E., Isaacson, M., Lee, L. A., May, P. K., Miriel, L., Sternberg, A., Van Natta, M., Wagoner, A., Wilson, L., & Yates, K. P.
- Affiliations
- Johns Hopkins University (US)
- Michigan Medicine (US)
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2018-01
- Volume
- 154
- Issue
- 1
- Pages
- 65-76.e11
- ISSN
- 0016-5085 (ISSN-L)
- PMC
- PMC5742047
- OpenAlex
- W2766218920
- Cited by
- 143
- References
- 35
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 14 · 2023: 16 · 2022: 18 · 2021: 22 · 2020: 19 · 2019: 25 · 2018: 16
- FWCI
- 16.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Gastroenterology (acceptedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR000093, UL1TR001105, UL1TR000135, UL1TR000433, UL1TR000424)
- National Institute of Diabetes and Digestive and Kidney Diseases (U01DK074008, U01DK073985, K23DK103911, U24DK074008, U01DK073974, U01DK074007, U01DK112193, U01DK073983, U01DK073975, U01DK074035)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Surgery › Nausea and vomiting management
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Infectious Diseases › Viral gastroenteritis research and epidemiology
- Keywords
- aprepitant, gastroparesis, chronic nausea, vomiting, NK1 receptor antagonists, symptom severity, adverse events, nausea severity
- MeSH terms
- Aprepitant, Adult, Antiemetics, Chronic Disease, Double-Blind Method, Female, Humans, Male, Middle Aged, Morpholines, Nausea, Vomiting, Treatment Outcome, Gastroparesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review